COINCIDE: CardineurOvascular dIsease aNd obstruCtive aIrway DiseasE

NCT07856667 | Not Yet Recruiting

• 1 other identifier: C_2_A.2-0062_016
• Study Type: observational
• Target: 350
• Locations: 0 countries
• Sites: N/A

Brief Summary

Patients with chronic obstructive pulmonary disease (COPD) and severe asthma frequently present with cardiovascular comorbidities that contribute substantially to morbidity and mortality. Early identification and appropriate management of cardiovascular disease are increasingly recognized as important components of comprehensive care for patients with obstructive airway diseases. The COINCIDE study is a prospective longitudinal observational cohort study conducted at the Department of Pulmonology, Medical University of Innsbruck. The study aims to systematically document cardiovascular comorbidities in patients with COPD and severe asthma and to evaluate their association with disease progression, therapeutic management, exacerbation rates, symptom burden, and pulmonary function over time. Clinical, functional, laboratory, and imaging data obtained as part of routine clinical care will be collected prospectively during two study visits separated by approximately 24 months. Up to 350 adult participants will be enrolled and followed over a period of five years.

Conditions

Chronic Obstructive Pulmonary Disease (COPD); Severe Asthma; Cardiovascular Diseases

Keywords

COPD; Chronic Obstructive Pulmonary Disease; Severe Asthma; Cardiovascular Comorbidity; Cardiovascular Disease; Pulmonology; Cohort Study; Longitudinal Study; Real World Data

Outcome Measures

Primary Outcomes (1)

• Prevalence and characterization of cardiovascular comorbidities

  Assessment of the prevalence, type, and distribution of cardiovascular comorbidities in patients with COPD and severe asthma based on clinical, laboratory, and imaging findings obtained during routine care.

  Baseline and 24 months

Secondary Outcomes (4)

• Exacerbation Frequency

  24 months

• Symptom Burden

  24 months

• Pulmonary Function

  Baseline and 24 months

• Treatment Modifications

  24 months

Interventions

Routine Clinical Care OTHER

Participants receive routine medical care according to local standards of care. No study-specific intervention, treatment allocation, or diagnostic procedure is performed.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients (≥18 years) with a diagnosis of COPD GOLD Group B or E or severe asthma according to current GOLD and GINA recommendations. Participants are recruited from the specialized pulmonary outpatient clinic of the Department of Internal Medicine II, Medical University of Innsbruck, and receive routine clinical care. Patients are followed prospectively to assess cardiovascular comorbidities and their impact on clinical outcomes.

You may qualify if:

• Male or female participants aged 18 years or older.
• Diagnosis of COPD GOLD Group B or E according to current GOLD recommendations, or severe asthma according to current GINA recommendations.
• Receiving care at the specialized pulmonary outpatient clinic of the Department of Internal Medicine II, Medical University of Innsbruck.
• Ability to provide written informed consent.

You may not qualify if:

• Age below 18 years.
• Inability or unwillingness to participate in study procedures.
• Inability or unwillingness to provide written informed consent.
• Planned transfer of care preventing longitudinal follow-up.
• Pregnancy.

Sponsors & Collaborators

• VASCage GmbH: lead

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Asthma; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchial Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Thomas Sonnweber

  Medical University Innsbruck

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Thomas Sonnweber

CONTACT

+43 512 504 82586; thomas.sonnweber@i-med.ac.at

Tina Pancheri

CONTACT

+43 51255443513; tina.pancheri@vascage.at

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2026
• First Posted: October 2, 2026
• Study Start (Estimated): October 15, 2026
• Primary Completion (Estimated): May 15, 2031
• Study Completion (Estimated): June 15, 2031
• Last Updated: October 2, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share